Floatz logo

mln9708

High Risk Smoldering Multiple Myeloma

Dana-Farber Cancer InstitutePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the High Risk Smoldering Multiple Myeloma cohort.

Asset / SponsorPhaseRating
Ibrutinib
Icahn School of Medicine at Mount Sinai
Phase 2CCC
Plerixafor
PETHEMA Foundation
Phase 2CCC
Cilta-Cel
PETHEMA Foundation
Phase 2CCC
CM336
Institute of Hematology & Blood Diseases Hospital, China
N/AD

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →